

EMMESSAR BIOTECH & NUTRITION LTD						
UNAUDITED FINANCIAL RESULTS AS ON 31st DECEMBER 2014						Rs. In Lakhs)
Particulars	Current Qtr Ended 31.12.2014 Unaudited	Preceding Qtr Ended 30.09.2014 Unaudited	Corresponding Qtr Ended 31.12.2013 Unaudited	Previous period Ended 31.12.2013 Unaudited	Current period Ended 31.12.2014 Unaudited	Previous Year Ended 31.03.2014 Audited
<b>PART I</b>						
01) Sales / Income from Operations (Gross)	153.06	41.79	19.29	88.49	220.53	140.00
Less: Excise Duty	5.60	3.28	0.79	1.28	9.05	3.14
(a) Net Sales / Income from operations	147.46	38.51	18.50	87.21	211.48	136.86
(b) Other Income	-	-	-	-	-	-
<b>Total Income</b>	<b>147.46</b>	<b>38.51</b>	<b>18.50</b>	<b>87.21</b>	<b>211.48</b>	<b>136.86</b>
02) Expenditure						
(a) (Increase) / Decrease in stock in trade	48.11	(26.30)	(36.12)	(36.30)	9.29	(9.08)
(b) Consumption of Raw materials	38.76	26.96	19.98	45.60	83.35	53.32
(c) Purchase of Traded goods	-	-	-	0.67	-	0.67
(d) Employee Cost	8.07	5.99	6.81	15.96	20.02	22.77
(e) Depreciation	1.71	1.71	1.75	5.25	5.14	19.59
(f) Other Expenditure	43.40	38.96	25.28	62.41	104.53	75.54
<b>(g) Expenditure (a to f)</b>	<b>140.05</b>	<b>47.32</b>	<b>17.70</b>	<b>93.59</b>	<b>222.33</b>	<b>162.81</b>
03) Profit from Operations before Other Income Interest & Exceptional items(1 - 2)	7.41	(8.81)	0.80	(6.38)	(10.85)	(25.95)
04) Other Income	0.78	1.66	0.14	8.38	5.36	9.22
05) Profit before Interest and Exceptional Items (3 + 4)	8.19	(7.15)	0.94	2.00	(5.49)	(16.73)
06) Interest	-	-	-	-	-	-
07) Profit after Interest but before Exceptional Items (5 - 6)	8.19	(7.15)	0.94	2.00	(5.49)	(16.73)
08) Exceptional Items	-	-	-	-	-	-
09) Profit / (-) Loss from Ordinary Activities Before Taxation (7 + 8)	8.19	(7.15)	0.94	2.00	(5.49)	(16.73)
10) Tax Expense	-	-	-	2.90	-	13.98
11) Net Profit / (Loss) from Ordinary Activities after Taxation (9 - 10)	8.19	(7.15)	0.94	(0.90)	(5.49)	(30.71)
12) Extraordinary Item (net of tax expense)	-	-	-	-	-	-
13) Net Profit / Loss for the period (11-12)	8.19	(7.15)	0.94	(0.90)	(5.49)	(30.71)
14) Paid-up Equity Share Capital (Face Value of the share)	499.61	499.61	499.61	499.61	499.61	499.61
	10.00	10.00	10.00	10.00	10.00	10.00
15) Reserves excluding Revaluation Reserve as per Balance Sheet of previous accounting year	-	-	-	-	-	-
16) Earning per Shares	0.16	(0.14)	0.02	(0.02)	(0.11)	(0.61)
a) Basic & diluted EPS before Extraordinary items for the period, for the year to date & for the previous year (not to be annualised)						
b) Basic & diluted EPS after Extraordinary items for the period, for the year to date & for the previous year (not to be annualised)						
<b>PART II</b>						
<b>A. PARTICULARS OF SHAREHOLDINGS</b>						
1) Public Shareholding						
- No. of Shares	2154731	2183781	2314394	2314394	2154731	2302713
- Percentage of Shareholding	43.13	43.71	46.32	46.32	43.13	46.09
2) Promoters & Promoter Group Shareholding						
a) Pledged / Encumbered						
- No. of Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as % of the total Share Capital of the Company)		Nil				Nil
b) Non Encumbered						
- No. of Shares	2841369	2812319.00	2681706	2681706	2841369	2693387
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as % of the total Share Capital of the Company)	56.87	56.29	53.68	53.68	56.87	53.91
Three Months ended 31.12.2014						
<b>B. INVESTORS COMPLAINTS</b>						
Pending at the beginning of the quarter	Nil					
Received during the quarter	Nil					
Disposed off during the quarter	Nil					
Remaining unresolved at the end of the quarter	Nil					

\* The above results were reviewed by the Audit Committee of the Board of Directors.

\* The Statutory Auditors have carried out a Limited Review of the results for the quarter ended December 31, 2014

\* The above Un-Audited Results were taken on record at the meeting of the Board of Directors held on 5th February, 2015.

By order of the Board  
MSR Ayyangar  
Managing Director

Mumbai  
5-Feb-15

**EMMESSAR BIOTECH & NUTRITION LIMITED****Quarter ended December 2014 Segment wise Revenue Results and Capital Employed**

[Rs. In Lakhs]

Particulars	Current Qtr	Preceding	Corresponding	Previous	Current period	Previous Year
	Ended 31.12.2014 Unaudited	Qtr Ended 30.09.2014 Unaudited	Qtr Ended 31.12.2013 Unaudited	period Ended 31.12.2013 Unaudited	Ended 31.12.2014 Unaudited	Ended 31.03.2014 Audited
<b>1. Segment Revenue (Net Sales / Income)</b>						
a. Healthcare	18.46	11.51	19.29	42.20	37.30	47.29
b. Fine Chemicals	129.00	27.00	-	45.01	174.18	90.64
c. Others	0.78	1.66	0.14	8.38	5.36	1.47
<b>Total:</b>	<b>148.24</b>	<b>40.17</b>	<b>19.43</b>	<b>95.59</b>	<b>216.84</b>	<b>139.40</b>
<b>Less: Inter Segment Revenue</b>	-	-	-	-	-	-
<b>Net Sales / Income from Operations</b>	<b>148.24</b>	<b>40.17</b>	<b>19.43</b>	<b>95.59</b>	<b>216.84</b>	<b>139.40</b>
<b>2. Segment Results (Profit / Loss) before Tax and Interest</b>						
a. Healthcare	13.41	5.60	9.17	12.37	22.19	32.06
b. Fine Chemicals	9.41	2.81	-	19.86	15.11	23.65
c. Others	0.78	1.66	0.14	8.38	5.36	0.80
<b>Total:</b>	<b>23.60</b>	<b>10.07</b>	<b>9.31</b>	<b>40.61</b>	<b>42.66</b>	<b>56.51</b>
<b>Less:</b>						
Interest	-	-	-	-	-	-
Other Unallocable Expenditure net off Unallocable Income	15.41	17.22	8.37	38.61	48.15	73.24
<b>Total Profit before Tax</b>	<b>8.19</b>	<b>(7.15)</b>	<b>0.94</b>	<b>2.00</b>	<b>(5.49)</b>	<b>(16.73)</b>
<b>3. Capital Employed (Segment Assets - Segment Liabilities)</b>						
a. Healthcare	6.63	16.49	15.34	15.34	6.63	11.42
b. Fine Chemicals	24.60	12.66	(25.30)	(25.30)	24.60	14.92
c. Others	(32.23)	(40.06)	26.67	26.67	(32.23)	(19.46)
<b>Total:</b>	<b>(1.00)</b>	<b>(10.91)</b>	<b>16.71</b>	<b>16.71</b>	<b>(1.00)</b>	<b>6.88</b>

**Note:** The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on 5th February, 2015.

Mumbai  
5th February, 2015

By order of the Board  
MSR Ayyangar  
Managing Director